1. Home
  2. CSPI vs AGEN Comparison

CSPI vs AGEN Comparison

Compare CSPI & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CSP Inc.

CSPI

CSP Inc.

HOLD

Current Price

$12.00

Market Cap

132.8M

Sector

Technology

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.34

Market Cap

126.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSPI
AGEN
Founded
1968
1994
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
132.8M
126.2M
IPO Year
1987
2000

Fundamental Metrics

Financial Performance
Metric
CSPI
AGEN
Price
$12.00
$3.34
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
18.3K
983.6K
Earning Date
02-09-2026
11-10-2025
Dividend Yield
1.04%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$58,730,000.00
$106,829,000.00
Revenue This Year
N/A
$23.68
Revenue Next Year
N/A
$23.17
P/E Ratio
N/A
N/A
Revenue Growth
6.36
N/A
52 Week Low
$9.65
$1.38
52 Week High
$21.95
$7.34

Technical Indicators

Market Signals
Indicator
CSPI
AGEN
Relative Strength Index (RSI) 44.92 41.53
Support Level $11.51 $3.01
Resistance Level $12.43 $4.87
Average True Range (ATR) 0.54 0.36
MACD -0.05 0.05
Stochastic Oscillator 35.35 15.95

Price Performance

Historical Comparison
CSPI
AGEN

About CSPI CSP Inc.

CSP Inc develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments, namely Technology Solutions, where the company focuses on value-added reseller integrated solutions, including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company designs, manufactures, and delivers products and services to customers that require specialized cybersecurity services, networking, and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates the majority of its revenue from the Americas.

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Share on Social Networks: